JP2023535483A5 - - Google Patents

Info

Publication number
JP2023535483A5
JP2023535483A5 JP2023505841A JP2023505841A JP2023535483A5 JP 2023535483 A5 JP2023535483 A5 JP 2023535483A5 JP 2023505841 A JP2023505841 A JP 2023505841A JP 2023505841 A JP2023505841 A JP 2023505841A JP 2023535483 A5 JP2023535483 A5 JP 2023535483A5
Authority
JP
Japan
Prior art keywords
compound
subject
use according
disease
tmt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023505841A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023535483A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/056971 external-priority patent/WO2022024062A1/en
Publication of JP2023535483A publication Critical patent/JP2023535483A/ja
Publication of JP2023535483A5 publication Critical patent/JP2023535483A5/ja
Pending legal-status Critical Current

Links

JP2023505841A 2020-07-30 2021-07-30 脳組織中のスフィンゴ糖脂質濃度を低減させるための方法およびそれを含む神経変性疾患の処置方法 Pending JP2023535483A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063059047P 2020-07-30 2020-07-30
US63/059,047 2020-07-30
US202063131120P 2020-12-28 2020-12-28
US63/131,120 2020-12-28
PCT/IB2021/056971 WO2022024062A1 (en) 2020-07-30 2021-07-30 Methods for reducing glycosphingolipid concentration in brain tissue and methods of treatment of neurodegenerative diseases involving the same

Publications (2)

Publication Number Publication Date
JP2023535483A JP2023535483A (ja) 2023-08-17
JP2023535483A5 true JP2023535483A5 (cg-RX-API-DMAC7.html) 2024-08-06

Family

ID=77265125

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023505841A Pending JP2023535483A (ja) 2020-07-30 2021-07-30 脳組織中のスフィンゴ糖脂質濃度を低減させるための方法およびそれを含む神経変性疾患の処置方法

Country Status (11)

Country Link
US (1) US20230372313A1 (cg-RX-API-DMAC7.html)
EP (1) EP4188381A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023535483A (cg-RX-API-DMAC7.html)
KR (1) KR20230047146A (cg-RX-API-DMAC7.html)
CN (1) CN116322679A (cg-RX-API-DMAC7.html)
AU (1) AU2021317180A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023001362A2 (cg-RX-API-DMAC7.html)
CA (1) CA3187086A1 (cg-RX-API-DMAC7.html)
IL (1) IL300096A (cg-RX-API-DMAC7.html)
MX (1) MX2023001285A (cg-RX-API-DMAC7.html)
WO (1) WO2022024062A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3920912T (pt) 2019-02-04 2025-09-09 Genzyme Corp Tratamento de ciliopatias usando inibidores da glucosilceramida sintase (gcs)
KR20260021150A (ko) 2024-08-05 2026-02-13 충북대학교 산학협력단 Gba1 돌연변이 보인자의 dj-1 발현수준에 따른 파킨슨병의 위험도 예측 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
LT2685986T (lt) * 2011-03-18 2020-03-10 Genzyme Corporation Gliukozilceramido sintazės slopiklis
JO3713B1 (ar) 2013-03-15 2021-01-31 Genzyme Corp أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
TW201642855A (zh) 2015-03-10 2016-12-16 健臻公司 用於治療蛋白質病變之方法
US10617713B2 (en) * 2016-03-08 2020-04-14 Neurocentria, Inc. Methods of modifying neuronal function by changing intracellular magnesium levels
EP3452045A1 (en) * 2016-05-04 2019-03-13 Lysosomal Therapeutics Inc. Methods of treatment and combination therapies using gcase activator heterobicyclic and related compounds
US10519157B2 (en) * 2018-02-09 2019-12-31 X-Cutag Therapeutics, Inc. Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof

Similar Documents

Publication Publication Date Title
US20240415788A1 (en) Ocular treatments for neurological and neuropsychiatric disorders
US8008285B2 (en) Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia
US11590107B2 (en) Methods for treating neurological disorders with α1A-AR partial agonists
TWI494293B (zh) 用於治療認知障礙之α-胺基醯胺衍生物
US20090023705A1 (en) Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders or attention deficit disorders
JPH0422889B2 (cg-RX-API-DMAC7.html)
JP2023512366A5 (cg-RX-API-DMAC7.html)
JP7337081B2 (ja) レストレスレッグズ症候群を治療するための治療薬
JP2012197304A (ja) ミオパシー関連性の覚醒障害を矯正することが意図される医薬品を製造するためのモダフィニルの使用
KR20130113430A (ko) 신경 연결의 발달 장애에 대한 erk 억제제
JP2022519274A5 (cg-RX-API-DMAC7.html)
JP2022520747A5 (cg-RX-API-DMAC7.html)
WO2022104383A1 (en) Pharmacological agents for treating conditions of the eye
JP4739760B2 (ja) バルビツール酸誘導体を使用する運動障害の治療方法
CA3187086A1 (en) Methods for reducing glycosphingolipid concentration in brain tissue and methods of treatment of neurodegenerative diseases involving the same
EP3556364B1 (en) Use of carbamate compound for preventing, alleviating, or treating tremors or tremor syndrome
JP3494651B2 (ja) 神経変性疾患の治療を目的とする医薬生成物の製造のためのエファロキサンおよびその誘導体の使用
Tarsy et al. Clonidine in Parkinson disease
Nakanishi et al. Side Effects, Contraindications, and Drug-Drug Interactions in the Use of Antiparkinsonian Drugs
US20240252579A1 (en) Use of cns-homing targeting peptides for treating neurological disorders
JP2003226642A (ja) 眼疾患予防及び/又は治療薬
JP2009508926A (ja) 神経変性疾患の治療のための2−アミノアルコール
JPS5850965B2 (ja) パ−キンソン病治療薬
HK40015061A (en) Use of carbamate compounds for preventing, alleviating, or treating tremors or tremor syndrome